Trials / Unknown
UnknownNCT05820906
Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer
Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer: A Single Center, Single Arm, Phase II Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of Cadonilimab in combination with Regorafenib and Gem-Cis chemotherapy in advanced biliary tract Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab+Regorafenib+GC | Cadonilimab:10mg/kg, iv,q3w,D1 Regorafenib: 80mg, po, orally once daily Gemcitabine:1000 mg/m2, iv, Q3W，D1,D8 Cisplatin:25 mg/m2, iv, Q3W, D1,D8 |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2024-09-01
- Completion
- 2025-09-01
- First posted
- 2023-04-20
- Last updated
- 2023-12-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05820906. Inclusion in this directory is not an endorsement.